SCHEMBL5359223

SCHEMBL5359223

O=C1Nc2ccc(S(=O)(=O)Nc3ccc(C(F)(F)F)cc3)cc2C1=Cc1cccn1-c1ccc(Cl)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MOGAT2 Q3SYC2 2/20 0.50
MAPT P10636 4/20 0.48
LMNA P02545 3/20 0.48
NPSR1 Q6W5P4 3/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
MGAT2 Q10469 5/20 0.47
PSD A5PKW4 1/20 0.45
HPGD P15428 3/20 0.44
KMT2A Q03164 3/20 0.44
NTSR1 P30989 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
ALDH1A1 P00352 1/20 0.44
ALOX12 P18054 1/20 0.44
MGAT1 P26572 1/20 0.43
MGAT3 Q09327 1/20 0.43
HTT P42858 2/20 0.43
MITF O75030 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5368431 0.86 MOGAT2 (0.55) MOGAT2MAPTLMNANPSR1NPC1
SCHEMBL7138959 0.81 MOGAT2 (0.54) MOGAT2MGAT2MGAT1MGAT3PKM
SCHEMBL5358368 0.81 MOGAT2 (0.61) MOGAT2MAPTMGAT2KMT2AMEN1
SCHEMBL5362152 0.80 MOGAT2 (0.52) MOGAT2MGAT2MGAT1MGAT3PKM
SCHEMBL5357745 0.80 MOGAT2 (0.58) MOGAT2MGAT2MGAT1MGAT3PKM
SCHEMBL5358922 0.79 PDPK1 (0.63) MOGAT2MAPTMGAT2KMT2AMEN1
SCHEMBL5366831 0.79 MOGAT2 (0.48) MOGAT2MAPTMGAT2MGAT1MGAT3
SCHEMBL7137726 0.79 MOGAT2 (0.57) MOGAT2MAPTMGAT2KMT2AMEN1
SCHEMBL7138855 0.79 MOGAT2 (0.55) MOGAT2MGAT2PKMLRRK2
SCHEMBL5373662 0.78 MOGAT2 (0.56) MOGAT2MAPTMGAT2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK MOGAT2 1159/4885MAPT 3048/4885LMNA 4250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.